【摘要】 目的分析瑞舒伐他汀联合法舒地尔治疗不稳定心绞痛患者的临床效果。方法方便选取来该院就医的不稳定心绞痛患者90例(2016年2月—2017年2月)作为该次研究的对象,通过动态化随机单双号分组的方法将其分为2组,分别给予常规治疗、瑞舒伐他汀联合法舒地尔治疗,对比2组患者血常规检测指标变化情况、心电图心率变异性指标对比情况、治疗效果、不良反应发生情况的差异性。结果观察组患者的TC:(4.81±1.11)mmol/L、TG:(1.32±0.51)mmol/L、LDL-C:(2.91±0.56)mmol/L、hs-CRP:(3.01±0.31)mmol/L、SDNN:(100.54±20.22)ms、SDANN:(59.56±6.97)ms、治疗总有效例数:42例;对照组患者的TC:(5.81±1.02)mmol/L、TG:(2.46±0.69)mmol/L、LDL-C:(3.94±0.61)mmol/L、hs-CRP:(6.54±0.77)mmol/L、SDNN:(80.20±10.23)ms、SDANN:(48.88±8.24)ms、治疗总有效例数:27例。2组结果比较,差异有统计学意义(P<0.05)。结论瑞舒伐他汀联合法舒地尔治疗不稳定心绞痛疾病具有的一定的应用价值,可改善患者临床症状,稳定患者病情,可推广。更多还原

【Abstract】 Objective This paper tries to evaluate the clinical efficacy of rosuvastatin combined with fasudil in the treatment of unstable angina pectoris. Methods 90 patients with unstable angina pectoris treated in this hospital from February2016 to February 2017 were convenient selected as the subjects of this study, and they were divided into two groups by dynamic randomized odd number method and were given conventional treatment, rosuvastatin combined with fasudil treatment,and then the blood test indicators changes, ECG heart rate variability indicators, treatment effect, adverse reactions of the two groups of patients were compared. Results In the observation group, TC was(4.81±1.11)mmol/L, TG was(1.32±0.51)mmol/L,LDL-C was(2.91±0.56)mmol/L, hs-CRP was(3.01±0.31)mmol/L, SDNN was(100.54±20.22)ms, SDANN was(59.56±6.97)ms,the total curative number was 42; while in the control group: TC was(5.81±1.02)mmol/L, TG was(2.46±0.69)mmol/L, LDLC was(3.94±0.61)mmol/L, hs-CRP was(6.54±0.77)mmol/L, SDNN was(80.20±10.23)ms, SDANN was(48.88±8.24)ms, and the total curative cases were 27. The difference between the two groups was significant(P<0.05). Conclusion The combination of rosuvastatin and fasudil in the treatment of unstable angina pectoris has certain application value, which can improve the clinical symptoms and stabilize the patient’s condition and can be applied.更多还原